Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2020 Sep 22

PMID 32957584

Citations 8

Authors

Ragheed Saoud

Nassib Abou Heidar

Alessia Cimadamore

Gladell P Paner

Affiliations

Soon will be listed here.

Abstract

In current practice, prostate cancer staging alone is not sufficient to adequately assess the patient's prognosis and plan the management strategies. Multiple clinicopathological parameters and risk tools for prostate cancer have been developed over the past decades to better characterize the disease and provide an enhanced assessment of prognosis. Herein, we review novel prognostic biomarkers and their integration into risk assessment models for prostate cancer focusing on their capability to help avoid unnecessary imaging studies, biopsies and diagnosis of low risk prostate cancers, to help in the decision-making process between active surveillance and treatment intervention, and to predict recurrence after radical prostatectomy. There is an imperative need of reliable biomarkers to stratify prostate cancer patients that may benefit from different management approaches. The integration of biomarkers panel with risk assessment models appears to improve prostate cancer diagnosis and management. However, integration of novel genomic biomarkers in future prognostic models requires further validation in their clinical efficacy, standardization, and cost-effectiveness in routine application.

Citing Articles

Overexpression of Transmembrane Phosphatase with Tensin homology (TPTE) in prostate cancer is clinically significant, suggesting its potential as a valuable biomarker.

Zainodini N, Abolhasani M, Mohsenzadegan M, Farajollahi M, Rismani E J Cancer Res Clin Oncol. 2024; 150(3):165.

PMID: 38546751 PMC: 10978697. DOI: 10.1007/s00432-024-05694-6.

Unraveling the Predictive Potential of Rapid Scoring in Pleural Infection: A Critical Review.

Annareddy Jr S, Ghewade B, Jadhav U, Wagh P Cureus. 2023; 15(9):e44515.

PMID: 37789994 PMC: 10544591. DOI: 10.7759/cureus.44515.

Li M, Zhang L, Feng M, Huang X J Immunol Res. 2022; 2022:3258400.

PMID: 35991123 PMC: 9385364. DOI: 10.1155/2022/3258400.

Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort.

Marenghi C, Qiu Z, Helleman J, Nieboer D, Rubio-Briones J, Carroll P Cancers (Basel). 2022; 14(15).

PMID: 35892817 PMC: 9332009. DOI: 10.3390/cancers14153558.

Bone marrow involvement in patients with metastatic castration sensitive prostate cancer.

Shahait M, Abu-Hijlih R, Salamat A, Heidar N, Sharaf B, Abuhijla F PLoS One. 2022; 17(7):e0270956.

PMID: 35862364 PMC: 9302741. DOI: 10.1371/journal.pone.0270956.

References

Verbeek J, Bangma C, Kweldam C, van der Kwast T, Kummerlin I, van Leenders G . Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. Urol Oncol. 2018; 37(2):138-144. DOI: 10.1016/j.urolonc.2018.11.021. View

Kattan M, Eastham J, Stapleton A, Wheeler T, Scardino P . A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90(10):766-71. DOI: 10.1093/jnci/90.10.766. View

de Rooij M, Hamoen E, Witjes J, Barentsz J, Rovers M . Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. Eur Urol. 2015; 70(2):233-45. DOI: 10.1016/j.eururo.2015.07.029. View

Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J . PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019; 37(6):490-503. DOI: 10.1200/JCO.18.00358. View

Osses D, Roobol M, Schoots I . Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis. Int J Mol Sci. 2019; 20(7). PMC: 6480079. DOI: 10.3390/ijms20071637. View

Spratt D, Yousefi K, Deheshi S, Ross A, Den R, Schaeffer E . Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. J Clin Oncol. 2017; 35(18):1991-1998. PMC: 6530581. DOI: 10.1200/JCO.2016.70.2811. View

Varma M, Cochlin D, Delahunt B, Kynaston H, Rees J, Rous B . TNM clinical staging of prostate cancer: issues and solutions. BJU Int. 2018; 123(3):382-384. DOI: 10.1111/bju.14589. View

Alford A, Brito J, Yadav K, Yadav S, Tewari A, Renzulli J . The Use of Biomarkers in Prostate Cancer Screening and Treatment. Rev Urol. 2018; 19(4):221-234. PMC: 5811879. DOI: 10.3909/riu0772. View

Beltran H, Rubin M . New strategies in prostate cancer: translating genomics into the clinic. Clin Cancer Res. 2012; 19(3):517-23. PMC: 4123124. DOI: 10.1158/1078-0432.CCR-12-1452. View

10.

Halabi S, Lin C, Small E, Armstrong A, Kaplan E, Petrylak D . Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst. 2013; 105(22):1729-37. PMC: 3833929. DOI: 10.1093/jnci/djt280. View

11.

Castro E, Goh C, Leongamornlert D, Saunders E, Tymrakiewicz M, Dadaev T . Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. Eur Urol. 2014; 68(2):186-93. DOI: 10.1016/j.eururo.2014.10.022. View

12.

Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M . Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013; 31(14):1748-57. PMC: 3641696. DOI: 10.1200/JCO.2012.43.1882. View

13.

Jamaspishvili T, Berman D, Ross A, Scher H, De Marzo A, Squire J . Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018; 15(4):222-234. PMC: 7472658. DOI: 10.1038/nrurol.2018.9. View

14.

Thompson I, Tangen C, Paradelo J, Lucia M, Miller G, Troyer D . Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009; 181(3):956-62. PMC: 3510761. DOI: 10.1016/j.juro.2008.11.032. View

15.

Spratt D, Zhang J, Santiago-Jimenez M, Dess R, Davis J, Den R . Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. J Clin Oncol. 2017; 36(6):581-590. PMC: 6530900. DOI: 10.1200/JCO.2017.74.2940. View

16.

Alberts A, Roobol M, Verbeek J, Schoots I, Chiu P, Osses D . Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. Eur Urol. 2018; 75(2):310-318. DOI: 10.1016/j.eururo.2018.07.031. View

17.

Cuzick J, Stone S, Fisher G, Yang Z, North B, Berney D . Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer. 2015; 113(3):382-9. PMC: 4522632. DOI: 10.1038/bjc.2015.223. View

18.

Olleik G, Kassouf W, Aprikian A, Hu J, Vanhuyse M, Cury F . Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review. J Natl Compr Canc Netw. 2018; 16(11):1340-1351. DOI: 10.6004/jnccn.2018.7055. View

19.

Halabi S, Lin C, Kelly W, Fizazi K, Moul J, Kaplan E . Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014; 32(7):671-7. PMC: 3927736. DOI: 10.1200/JCO.2013.52.3696. View

20.

Fossati N, Karnes R, Boorjian S, Moschini M, Morlacco A, Bossi A . Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. Eur Urol. 2016; 71(6):886-893. DOI: 10.1016/j.eururo.2016.07.028. View